Skip to main content

Biodesix Partners with Association of Pulmonary Advanced Practice Providers (APAPP) to Deliver Nation’s First Medical Education for APPs on Biomarkers in Lung Nodule and Lung Cancer Programs

Written by Customer Service on . Posted in Public Companies.

Nation’s first CME-accredited course for APPs on clinical application of diagnostic biomarkers in Lung Nodule and Lung Cancer patient programs

LOUISVILLE, Colo., June 10, 2025 (GLOBE NEWSWIRE) — Biodesix, Inc. (Nasdaq: BDSX), a leading diagnostic solutions company, announced today that it is partnering with the Association of Pulmonary Advanced Practice Providers (APAPP) to bring new educational programs aimed at their professional membership to better provide access and timely care to patients at risk for lung cancer.

In this novel partnership, the two organizations will launch new educational resources for Lung Health providers on innovative lung nodule risk assessment testing, such as the Nodify Lung® blood-based tests, or cancer treatment decision support testing, such as the IQLung® blood-based tests. According to the American Lung Association, Lung Cancer is the deadliest of all cancers, killing almost as many Americans annually as breast, prostate, and colon cancers combined.

As part of this collaboration, Biodesix and APAPP will introduce new programs to educate and empower providers that practice in diverse care settings, both rural and metropolitan, managing large diverse patient populations, often with minimal resources.

“We are excited to collaborate in building awareness on how to improve patient care and outcomes for earlier detection and diagnosis of lung cancer through Biodesix blood tests,” said Scott Hutton, CEO of Biodesix. “Sadly, the latest statistics indicate that 1 in 18 Americans will receive a lung cancer diagnosis in their lifetime. We want patients and providers to know that there are diagnostic options available to expedite earlier diagnosis and to personalize treatment decisions.”

“APPs are some of the most patient-centric and patient-driven individuals within the healthcare system,” said Corinne Young, President & Founder, Association of Pulmonary Advanced Practice Providers. “An important part of supporting patients with lung nodules or with a lung cancer diagnosis is to be educated on the diagnostic tools that can give the patients peace of mind. APAPP is happy to partner with Biodesix to further our commitment to support our professional members so that they may provide the best patient care options.”

About APAPP

APAPP is the first association solely focused on Advanced Practice Providers (APPs) working in the realms of pulmonary medicine. For the first time, Nurse Practitioners and Physician Assistants can join together under one membership to work towards a common goal of excellence in pulmonology medicine.

About Biodesix

Biodesix is a leading diagnostic solutions company, driven to improve clinical care and outcomes for patients. Biodesix Diagnostic Tests, marketed as Nodify Lung® Nodule Risk Assessment and IQLung® Cancer Treatment Guidance, support clinical decisions to expedite personalized care and improve outcomes for patients with lung disease. Biodesix Development Services enable the world’s leading biopharmaceutical, life sciences, and research institutions with scientific, technological, and operational capabilities that fuel the development of diagnostic tests, tools, and therapeutics. For more information, visit biodesix.com.

Contacts:

APAPP:
Corinne Young, MSN, FNP, FCCP
President & Founder, APAPP
corinne@pulmapp.com
(719) 425-7040

Biodesix:
Natalie St. Denis, Director Corporate Communications
natalie.stdenis@biodesix.com 
(720) 925-9285

Disclaimer & Cookie Notice

Welcome to GOLDEA services for Professionals

Before you continue, please confirm the following:

Professional advisers only

I am a professional adviser and would like to visit the GOLDEA CAPITAL for Professionals website.

Important Notice for Investors:

The services and products offered by Goldalea Capital Ltd. are intended exclusively for professional market participants as defined by applicable laws and regulations. This typically includes institutional investors, qualified investors, and high-net-worth individuals who have sufficient knowledge, experience, resources, and independence to assess the risks of trading on their own.

No Investment Advice:

The information, analyses, and market data provided are for general information purposes only and do not constitute individual investment advice. They should not be construed as a basis for investment decisions and do not take into account the specific investment objectives, financial situation, or individual needs of any recipient.

High Risks:

Trading in financial instruments is associated with significant risks and may result in the complete loss of the invested capital. Goldalea Capital Ltd. accepts no liability for losses incurred as a result of the use of the information provided or the execution of transactions.

Sole Responsibility:

The decision to invest or not to invest is solely the responsibility of the investor. Investors should obtain comprehensive information about the risks involved before making any investment decision and, if necessary, seek independent advice.

No Guarantees:

Goldalea Capital Ltd. makes no warranties or representations as to the accuracy, completeness, or timeliness of the information provided. Markets are subject to constant change, and past performance is not a reliable indicator of future results.

Regional Restrictions:

The services offered by Goldalea Capital Ltd. may not be available to all persons or in all countries. It is the responsibility of the investor to ensure that they are authorized to use the services offered.

Please note: This disclaimer is for general information purposes only and does not replace individual legal or tax advice.